ANI Pharmaceuticals, Inc. (ANIP) Investor Relations Documents

ANI Pharmaceuticals, Inc. (ANIP) investor relations documents from the company's IR site: 1 presentation, 39 press releases; latest deck 2025-07-23. Read in-app with summaries. First-party data.

NEW DAY STUDY RESULTS PRESENTATION: The NEW DAY clinical trial evaluated ILUVIEN as a baseline therapy for early diabetic macular edema (DME) compared to aflibercept over 72 weeks.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-07Press releaseANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
2026-07-24Press releaseANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
2026-07-16Press releaseANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
2026-07-13Press releaseANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Tria
2026-05-27Press releaseANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-08Press releaseANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
2026-04-24Press releaseANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
2026-04-20Press releaseANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
2026-04-13Press releaseANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
2026-04-08Press releaseANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
2026-04-07Press releaseANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
2026-02-24Press releaseANI Pharmaceuticals to Present at Upcoming Investor Conferences
2026-02-13Press releaseANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
2026-01-12Press releaseANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Prio
2026-01-06Press releaseANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Press releasePress Release
Press releaseANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET
Press releasePress Release
Press releaseANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
2025-07-23Earnings deckNEW DAY STUDY RESULTS PRESENTATION
Press releasePress Release
Press releaseANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET
Press releasePress Release
Press releaseANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook
Press releasePress Release
Press releaseANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET
Press releasePress Release
Press releaseANI Pharmaceuticals to Discuss Second Quarter 2024 Financial Results on August 6, 2024, at 8:30 a.m. ET
Press releasePress Release
Press releaseANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
Press releasePress Release
Press releasePress Release
Press releaseANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET
Press releasePress Release
Press releaseANI Pharmaceuticals to Discuss Second Quarter 2023 Financial Results on August 9, 2023, at 8:30 a.m. ET
Press releasePress Release
Press releaseANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET
Press releasePress Release
Press releasePress Release
Press releaseANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8:00 a.m. ET

ANIP overview · ANIP earnings · ANIP financials · ANIP KPIs · ANIP documents · ANIP ownership · ANIP peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.